Table 1 Baseline patient demographics, clinical and functional characteristics
Responders (n = 13) | Non-responders (n = 7) | P value | |
|---|---|---|---|
Female, number (%) | 12 (92) | 6 (86) | 0.589 |
Age, years | 51.8 ± 13.3 | 54.4 ± 5.5 | 0.621 |
Length, cm | 165.8 ± 8.7 | 166.6 ± 6.7 | 0.835 |
Weight, kg | 71.2 (62.5–89.7) | 70.0 (57.0–91.0) | 0.643 |
IgM RF positivity, number (%) | 10 (77) | 5 (71) | 0.594 |
RF titer, IU/mL | 10.0 (8.4–84.5) | 25.0 (0.0–176.0) | 0.765 |
Anti-CCP positivity, number (%) | 9 (79) | 5 (71) | 0.664 |
aCCP titer, U/mL | 27.0 (0.0–193.5) | 82.0 (0.0–270) | 0.757 |
Disease duration, years | 8.0 (3.5–16.0) | 9.0 (4.0–21.0) | 0.757 |
Current smokers, number (%) | 3 (23) | 3 (43) | 0.336 |
DAS28 | 5.6 (4.9–6.1) | 5.0 (4.0–7.1) | 0.643 |
Swollen joint count | 11.0 (7.5–14.0) | 11.0 (8.0–18.0) | 0.938 |
Tender joint count | 14.0 (6.5–16.0) | 8.0 (0.0–20.0) | 0.588 |
HAQ | 1.4 (0.8–1.8) | 1.1 (0.5–2.0) | 0.938 |
VAS | 60.0 (52.5–64.0) | 70.0 (40.0–75.0) | 0.485 |
CRP, mg/mLa | 6.0 (2.8–18.0) | 4.0 (2.5–32.0) | 0.699 |
ESR, mm/h | 21.0 (10.5–41.0) | 12 (5.0–36.0) | 0.485 |
DMARD use, number (%) | 12 (92) | 5 (71) | 0.270 |
Prednisone, number (%) | 6 (46) | 2 (29) | 0.642 |
Dosage in mg/day | 5 (0.0–7.5) | 7.5 (0.0–10.0) | 0.438 |